Olga Shestova
Overview
Explore the profile of Olga Shestova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M, et al.
Nat Biotechnol
. 2020 May;
38(8):947-953.
PMID: 32361713
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging. Given the unique effector functions of macrophages and...
12.
Singh N, Lee Y, Shestova O, Ravikumar P, Hayer K, Hong S, et al.
Cancer Discov
. 2020 Feb;
10(4):552-567.
PMID: 32001516
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive....
13.
Ruella M, Barrett D, Shestova O, Perazzelli J, Posey A, Hong S, et al.
Blood
. 2019 Nov;
135(7):505-509.
PMID: 31703119
Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19+ leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric...
14.
Guerrero-Juarez C, Dedhia P, Jin S, Ruiz-Vega R, Ma D, Liu Y, et al.
Nat Commun
. 2019 Feb;
10(1):650.
PMID: 30737373
During wound healing in adult mouse skin, hair follicles and then adipocytes regenerate. Adipocytes regenerate from myofibroblasts, a specialized contractile wound fibroblast. Here we study wound fibroblast diversity using single-cell...
15.
Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D, et al.
Nat Med
. 2018 Oct;
24(10):1499-1503.
PMID: 30275568
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19 leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into...
16.
Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T, et al.
Cell
. 2018 Jun;
173(6):1439-1453.e19.
PMID: 29856956
The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute...
17.
Ruella M, Klichinsky M, Kenderian S, Shestova O, Ziober A, Kraft D, et al.
Cancer Discov
. 2017 Jun;
7(10):1154-1167.
PMID: 28576927
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized...
18.
Tasian S, Kenderian S, Shen F, Ruella M, Shestova O, Kozlowski M, et al.
Blood
. 2017 Mar;
129(17):2395-2407.
PMID: 28246194
We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at the cost of severe hematologic...
19.
Glisovic-Aplenc T, Gill S, Spruce L, Smith I, Fazelinia H, Shestova O, et al.
Proteomics
. 2017 Jan;
17(7).
PMID: 28116781
The proteins of the cellular plasma membrane (PM) perform important functions relating to homeostasis and intercellular communication. Due to its overall low cellular abundance, amphipathic character, and low membrane-to-cytoplasm ratio,...
20.
Chiang M, Wang Q, Gormley A, Stein S, Xu L, Shestova O, et al.
Blood
. 2016 Sep;
128(18):2229-2240.
PMID: 27670423
Activating NOTCH1 mutations are frequent in human T-cell acute lymphoblastic leukemia (T-ALL) and Notch inhibitors (γ-secretase inhibitors [GSIs]) have produced responses in patients with relapsed, refractory disease. However, sustained responses,...